• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

异烟肼在人体内形成的有毒肼类代谢产物的药代动力学。

Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans.

作者信息

Lauterburg B H, Smith C V, Todd E L, Mitchell J R

出版信息

J Pharmacol Exp Ther. 1985 Dec;235(3):566-70.

PMID:4078724
Abstract

The plasma concentrations of isoniazid and its hydrazino metabolites, acetylisoniazid, acetylhydrazine and diacetylhydrazine, were measured by gas chromatography-mass spectrometry in 12 healthy subjects after the ingestion of 300 mg of isoniazid. The area under the plasma concentration-time curve of acetylisoniazid and diacetylhydrazine increased with increasing rate of acetylation of isoniazid. In contrast, the area under the plasma concentration-time curve of acetylhydrazine, the postulated precursor of a toxic metabolite formed from isoniazid, was greater in slow acetylators. This occurred even though rapid acetylators generated more acetylisoniazid and thus more acetylhydrazine from isoniazid, because the rapid acetylators also acetylated acetylhydrazine faster to diacetylhydrazine than did the slow acetylators. Due to this complex relationship between area under the plasma concentration-time curve of acetylhydrazine and the rate of isoniazid acetylation (i.e., a faster rate of formation of acetylhydrazine is accompanied by a faster clearance to diacetylhydrazine), the rate of acetylation of isoniazid minimally influences the exposure of most patients to acetylhydrazine. This pharmacokinetic analysis, however, also shows that the apparent plasma half-life of acetylhydrazine is about five times longer than the plasma half-life of isoniazid, and thus repeated doses of isoniazid should lead to an accumulation of acetylhydrazine in the slowest acetylators in which the plasma half-life of acetylhydrazine is 20-plus hr.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在12名健康受试者口服300毫克异烟肼后,采用气相色谱 - 质谱法测定了异烟肼及其肼基代谢产物乙酰异烟肼、乙酰肼和二乙酰肼的血浆浓度。乙酰异烟肼和二乙酰肼的血浆浓度 - 时间曲线下面积随异烟肼乙酰化速率的增加而增加。相比之下,异烟肼形成的有毒代谢产物的假定前体乙酰肼的血浆浓度 - 时间曲线下面积在慢乙酰化者中更大。尽管快乙酰化者从异烟肼生成更多的乙酰异烟肼,从而生成更多的乙酰肼,但这种情况仍然发生,因为快乙酰化者将乙酰肼乙酰化为二乙酰肼的速度也比慢乙酰化者更快。由于乙酰肼的血浆浓度 - 时间曲线下面积与异烟肼乙酰化速率之间存在这种复杂关系(即乙酰肼形成速度越快,其清除为二乙酰肼的速度也越快),异烟肼的乙酰化速率对大多数患者乙酰肼的暴露影响最小。然而,该药代动力学分析还表明,乙酰肼的表观血浆半衰期约为异烟肼血浆半衰期的五倍,因此重复给予异烟肼会导致乙酰肼在最慢乙酰化者体内蓄积,其中乙酰肼的血浆半衰期超过20小时。(摘要截短于250字)

相似文献

1
Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans.异烟肼在人体内形成的有毒肼类代谢产物的药代动力学。
J Pharmacol Exp Ther. 1985 Dec;235(3):566-70.
2
Acetylation of acetylhydrazine, the toxic metabolite of isoniazid, in humans. Inhibition by concomitant administration of isoniazid.
J Pharmacol Exp Ther. 1987 Nov;243(2):686-9.
3
Oxidation of hydrazine metabolites formed from isoniazid.异烟肼形成的肼代谢物的氧化作用。
Clin Pharmacol Ther. 1985 Nov;38(5):566-71. doi: 10.1038/clpt.1985.225.
4
Increased urinary excretion of toxic hydrazino metabolites of isoniazid by slow acetylators. Effect of a slow-release preparation of isoniazid.慢乙酰化者异烟肼有毒肼类代谢产物的尿排泄增加。异烟肼缓释制剂的作用。
Eur J Clin Pharmacol. 1987;33(3):283-6. doi: 10.1007/BF00637563.
5
Monoacetylhydrazine as a metabolite of isoniazid in man.单乙酰肼作为异烟肼在人体内的代谢产物。
Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):602-8. doi: 10.1002/cpt1977225part1602.
6
Factors affecting the metabolism of [14C]acetylhydrazine in rats.
Drug Metab Dispos. 1978 Sep-Oct;6(5):561-6.
7
Studies on the effects of isoniazid on acetylhydrazine metabolism in vivo and in vitro.
Drug Metab Dispos. 1979 Jul-Aug;7(4):237-40.
8
Determination of isoniazid, acetylisoniazid, acetylhydrazine and diacetylhydrazine in biological fluids by high-performance liquid chromatography.
J Chromatogr. 1985 Feb 27;338(1):113-22. doi: 10.1016/0378-4347(85)80075-x.
9
Metabolism of [14C]acetylisoniazid and [14C]acetylhydrazine by the rat and rabbit.
Fundam Appl Toxicol. 1984 Aug;4(4):646-53.
10
Studies on the role of acetylhydrazine in isoniazid hepatotoxicity.
Arch Toxicol Suppl. 1979(2):1-8. doi: 10.1007/978-3-642-67265-1_1.

引用本文的文献

1
Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population.异烟肼及其代谢产物乙酰异烟肼在中国人群中的群体药代动力学与药效学
Front Pharmacol. 2022 Jul 19;13:932686. doi: 10.3389/fphar.2022.932686. eCollection 2022.
2
Isonicotinylation is a histone mark induced by the anti-tuberculosis first-line drug isoniazid.异烟腙化是一种组蛋白标记,由抗结核一线药物异烟肼诱导产生。
Nat Commun. 2021 Sep 20;12(1):5548. doi: 10.1038/s41467-021-25867-y.
3
-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and -Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment.
南非祖鲁语人群中乙酰转移酶 2 基因型与抗结核治疗期间异烟肼和乙酰异烟肼药代动力学的关系。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02376-19.
4
Genomewide Association Study Confirming the Association of with Susceptibility to Antituberculosis Drug-Induced Liver Injury in Thai Patients.全基因组关联研究证实 与泰国患者抗结核药物性肝损伤易感性的关联。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.02692-18. Print 2019 Aug.
5
variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis.抗结核药物相关的变异和毒性:系统评价和荟萃分析。
Int J Tuberc Lung Dis. 2019 Mar 1;23(3):293-305. doi: 10.5588/ijtld.18.0324.
6
Pharmacogenetic association between gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence.基因多态性与异烟肼诱导肝毒性的药物遗传学关联:试验序列荟萃分析证据。
Biosci Rep. 2019 Jan 15;39(1). doi: 10.1042/BSR20180845. Print 2019 Jan 31.
7
Induction of protective autophagy against apoptosis in HepG2 cells by isoniazid independent of the p38 signaling pathway.异烟肼通过独立于p38信号通路诱导HepG2细胞产生抗凋亡的保护性自噬。
Toxicol Res (Camb). 2016 Apr 4;5(3):963-972. doi: 10.1039/c5tx00470e. eCollection 2016 May 1.
8
Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol).遗传变异对抗结核药物毒性的影响:系统评价和荟萃分析(方案)。
Syst Rev. 2017 Jul 13;6(1):142. doi: 10.1186/s13643-017-0533-4.
9
Isoniazid metabolism and hepatotoxicity.异烟肼代谢与肝毒性。
Acta Pharm Sin B. 2016 Sep;6(5):384-392. doi: 10.1016/j.apsb.2016.07.014. Epub 2016 Aug 3.
10
A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.异烟肼的生理药代动力学模型及其在结核病个体化化疗中的应用
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6134-45. doi: 10.1128/AAC.00508-16. Print 2016 Oct.